๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Localisation by in situ hybridisation of S100A4 (p9Ka) mrna in primary human breast tumour specimens

โœ Scribed by Leonid L. Nikitenko; Bryony H. Lloyd; Philip S. Rudland; Simon Fear; Roger Barraclough


Book ID
102650013
Publisher
John Wiley and Sons
Year
2000
Tongue
French
Weight
712 KB
Volume
86
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis


Rodent S100A4 (p9Ka) induces a metastatic phenotype in benign rat mammary tumour cells and cooperates with the neu oncogene to produce metastatic tumours in a transgenic mouse model system. Human S100A4 possesses similar metastasis-inducing properties. S100A4 mRNA is now sought in human breast tumour-derived cell lines and tumour specimens. S100A4 mRNA is present in some cell lines derived from malignant breast cancers, but is not detectable in cells derived from benign breast tumours. In human tumour specimens, using in situ hybridisation, the mRNA for S100A4 is localised to the epithelial cells of carcinoma specimens, and in some normal breast specimens, to a stromal region surrounding the epithelial ducts. In carcinoma specimens, S100A4 mRNA is also found in the stromal region surrounding islands of cancer cells. For both the epithelial and stromal components, S100A4 mRNA is present at a higher level in carcinomas relative to benign breast tumour specimens. In general, there is a concordance between the S100A4 mRNA signal from the epithelial and stromal elements of the same carcinoma specimens. Using Northern blotting techniques, these results have been extended to a panel of 137 benign and malignant breast tumour specimens. The results show that S100A4 mRNA occurs in the more-malignant, rather than in the more-benign tumour specimens. Int.


๐Ÿ“œ SIMILAR VOLUMES


Comparison of the metastasis-inducing pr
โœ Angela M. Platt-Higgins; Christine A. Renshaw; Christopher R. West; John H.R. Wi ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 293 KB ๐Ÿ‘ 1 views

Our aim was to compare the occurrence and prognostic significance over 14 -20 years of immunocytochemically detected S100A4 and other tumour variables in primary tumours from 349 patients with operable breast cancer. For a cut-off of 1% staining of the malignant cells, the antibody to S100A4 stains